Taiwan-based EirGenix has announced a new milestone in collaboration with Merck. What began as a trusted supplier–customer relationship has now evolved into a strategic innovation partnership—driving the next generation of smart biomanufacturing.
Through a non-binding Memorandum of Understanding (MoU), EirGenix will integrate Merck’s cutting-edge digital and process platforms into its manufacturing capabilities, bringing closer to a highly connected, data-driven future-
ProCellics™ Raman Analyzer – Real-time monitoring for cell culture optimization
Mobius® MCC Continuous Chromatography – Enhancing purification efficiency and flexibility
Bio4C™ Software Platform – Transforming data into actionable insights for decision-making
By combining Merck’s technologies with EirGenix’s expertise in biologics development and manufacturing, the companies aim towards creating a new blueprint for digital transformation in biopharma.
This partnership represents more than just technology adoption, it is a shared vision to accelerate Taiwan’s biotech industry toward greater efficiency, sustainability, and global competitiveness.
